Republic Healthcare Valuation

Q: What is the Fair Price of 8357 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

8357 (HK$0.08) is trading below our estimate of [[fair value]] (HK$1.71)

Is 8357 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 8357 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 8357 (HK$0.08) is trading below our estimate of fair value (HK$1.71)

Significantly Below Fair Value: 8357 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 8357?

Key metric: As 8357 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 8357. This is calculated by dividing 8357's market cap by their current revenue.
What is 8357's PS Ratio?
PS Ratio	0.9x
Sales	S$9.27m
Market Cap	S$10.79m

8357 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 8357's PS Ratio compare to its peers?

The above table shows the PS ratio for 8357 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3.1x
2159 Mediwelcome Healthcare Management & Technology	0.2x	n/a	HK$74.0m
8307 Medicskin Holdings	1.6x	n/a	HK$75.0m
8437 RMH Holdings	9.4x	n/a	HK$373.0m
1406 Clarity Medical Group Holding	1.1x	n/a	HK$211.6m
8357 Republic Healthcare	0.9x	n/a	HK$49.3m

Price-To-Sales vs Peers: 8357 is good value based on its Price-To-Sales Ratio (0.9x) compared to the peer average (3.1x).

Price to Sales Ratio vs Industry

How does 8357's PS Ratio compare vs other companies in the HK Healthcare Industry?

11 Companies	Price / Sales	Estimated Growth	Market Cap
1099 Sinopharm Group	0.1x	5.8%	US$8.26b
9885 YSB	0.2x	n/a	US$512.37m
2289 Charmacy Pharmaceutical	0.2x	n/a	US$128.47m
9955 ClouDr Group	0.2x	23.5%	US$89.03m

11 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 8357 is expensive based on its Price-To-Sales Ratio (0.9x) compared to the Hong Kong Healthcare industry average (0.9x).

Price to Sales Ratio vs Fair Ratio

What is 8357's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

8357 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.9x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 8357's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Hygeia Healthcare Holdings

HK$10.2b

Offers oncology healthcare services in the People's Republic of China.

6078

HK$16.40

-6.6%

-66.9%

Hygeia Healthcare Holdings

HK$10.2b

Offers oncology healthcare services in the People's Republic of China.

6078

HK$16.40

-6.6%

-66.9%

Sinopharm Group

HK$62.6b

Engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China.

1099

HK$20.60

-0.2%

6.1%